DNALite Therapeutics' Seed Round

DNALite Therapeutics raised a round of funding on September 12, 2017. Investors include IndieBio.

DNALite Therapeutics is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies. Its current target is Familial Adenomatous Polyposis (FAP)…

Articles about DNALite Therapeutics' Seed Round: